These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19287462)

  • 1. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance.
    Chen X; Zhang Z; Feng Y; Fadare O; Wang J; Ai Z; Jin H; Gu C; Zheng W
    Mod Pathol; 2009 May; 22(5):699-708. PubMed ID: 19287462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
    Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
    Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.
    Fan R; Wang Y; Wang Y; Wei L; Zheng W
    Am J Transl Res; 2017; 9(3):1483-1491. PubMed ID: 28386373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
    Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
    Ørbo A; Arnes M; Lyså LM; Borgfeldt C; Straume B
    Br J Cancer; 2016 Sep; 115(6):725-30. PubMed ID: 27537387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
    Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
    Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
    Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
    Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
    Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
    Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPAG9 May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin.
    Li C; Bai Y; Yan L; Zhang L; Zhang H; Li M; Zhao M; Gao Y; Zhao X
    Gynecol Obstet Invest; 2016; 81(3):267-74. PubMed ID: 26334303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
    Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
    Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
    Amezcua CA; Zheng W; Muderspach LI; Felix JC
    Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia.
    Miranda MC; Mazur MT
    Arch Pathol Lab Med; 1995 May; 119(5):458-60. PubMed ID: 7748076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
    Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
    BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association of progestin-induced cystic endometrial hyperplasia with GH gene expression in the canine uterus.
    Kooistra HS; Okkens AC; Mol JA; van Garderen E; Kirpensteijn J; Rijnberk A
    J Reprod Fertil Suppl; 1997; 51():355-61. PubMed ID: 9404306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving response to progestin treatment of low-grade endometrial cancer.
    Baxter E; Brennan DJ; McAlpine JN; Mueller JJ; Amant F; van Gent MDJM; Huntsman DG; Coleman RL; Westin SN; Yates MS; Krakstad C; Quinn MA; Janda M; Obermair A
    Int J Gynecol Cancer; 2020 Nov; 30(11):1811-1823. PubMed ID: 32381512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.